Trial Search Results

Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery

The purpose of this study is to evaluate the role of GLP-1 in causing extreme postprandial glucose reductions after bariatric surgery in a subset of patients who have severe symptomatic hypoglycemia.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Tracey McLaughlin

Stanford Investigator(s):


  • Drug: Exendin (9-39)
  • Other: Placebo


Phase 1


Inclusion Criteria:

   - Men and women ages 18-65

   - BMI 25-40 with a clinical diagnosis of severe symptomatic hypoglycemia after bariatric

Exclusion Criteria:

   - Acute medical illness, such as acute bacterial or viral syndrome, febrile illness,
   acute abdominal symptoms, orthopedic injury within one week

   - History of cardiac failure, renal insufficiency (estimated Crcl<30cc/min), hepatic
   insufficiency, chronic obstructive pulmonary disease, anemia (Hct<30%), or
   uncontrolled hypertension (SBP>160 or DBP>100)

   - Pregnancy

   - Use of medications that affect glucose metabolism

   - Fasting glucose >150 or HbA1c>7.5 on Metformin

   - Women of childbearing potential (will have a pregnancy test, in addition use of
   abstinence for at least one month prior to study or use two types of contraceptives,
   hormonal implant or Depo Provera)

   - Active, uncontrolled psychiatric disease

   - Participating in other studies or have received investigational medications within the
   past month or 5 half-lives of the drug, whichever is longer.

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Colleen Craig, M.D.
Not Recruiting